ADAR1 Capital Management, LLC, 10% Owner at InMed Pharmaceuticals Inc. (INM), bought 468,551 shares at $1.60 ($722K) on 2026-05-19, disclosed to the SEC on 2026-05-21.
ADAR1 Capital Management executed the largest insider purchase in INM's history, buying 68,551 shares at $1.60 on May 19. This timing aligns with the company's announcement of a $290 million merger with Mentari Therapeutics to focus on migraine prevention, supporting the recent 165% five-day rally.
INM has rallied 165% over the past five days to reach $1.725, trading just 3.63% below its 52-week high of $1.79.
The company announced a merger with Mentari Therapeutics on May 19, 2026, backed by a $290 million financing to fund operations and clinical milestones. Additionally, the largest-ever insider purchase by ADAR1 Capital on the same day provides strong conviction for the migraine prevention strategy.
The company trades at a forward P/E of -0.28, indicating current losses, and carries a short interest of 1.08% of the float.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.50 | 200,000 | $300K | 41.5% |
| 2 | $1.56 | 200,000 | $312K | 43.3% |
| 3 | $1.60 | 68,551 | $110K | 15.2% |
| Total | $1.54 avg | 468,551 | $722K | 100% |
| Filing → |
| INM | BUY | 2026-10-05 | $57K | — | Filing → |
| INM | BUY | 2026-09-16 | $118K | — | Filing → |
| TENX | BUY | 2026-09-08 | $1.6M | — | Filing → |